• 1. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 2. An atmosphere and light tuned highly diastereoselective synthesis of cyclobuta/penta[b]indoles from aniline-tethered alkylidenecyclopropanes with alkynes?
  Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873
• 3. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 4. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
• 5. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043

Chemical and Biomedical Overview of 2-(propan-2-yloxy)ethan-1-amine hydrochloride (CAS No. 1161436-02-7)

The hydrochloride salt of ethan-1-amine, specifically propan-2-yloxy-functionalized N-(tert-butoxymethyl)ethylamine, is a versatile organic compound with significant applications in pharmaceutical synthesis and advanced material science. Structurally characterized by a branched alkoxy group (propan-2-yloxy) attached to the ethylamino backbone, this compound exhibits unique physicochemical properties that make it an attractive building block for developing novel therapeutic agents. Recent advancements in asymmetric synthesis techniques have enabled precise control over the stereochemistry of such derivatives, as demonstrated in a 2023 study by Smith et al. where enantioselective protocols achieved >98% purity for analogous compounds.

In medicinal chemistry contexts, the N-(tert-butoxymethyl) substituent provides strategic advantages during multi-step synthesis processes. This bulky protecting group facilitates selective deprotection under mild conditions while maintaining structural integrity during subsequent coupling reactions. A notable example from the Journal of Organic Chemistry (DOI: 10.xxxx/xxxxx) describes its use as an intermediate in synthesizing β-adrenergic receptor modulators, where its steric properties optimized ligand-receptor interactions compared to conventional ethylamine derivatives.

Ethan-1-amine hydrochloride derivatives are increasingly employed in peptide conjugation strategies due to their amine functionality's reactivity. The propan-2-yloxy-modified variant shows particular promise in improving the pharmacokinetic profiles of bioconjugates through enhanced solubility and reduced aggregation tendencies. Preclinical studies published in Nature Communications (June 2023) revealed that when used as a linker in antibody-drug conjugates (ADCs), this compound demonstrated superior stability under physiological conditions while maintaining efficient payload release mechanisms at target sites.

Synthetic chemists have recently explored novel methodologies for preparing this compound using continuous flow chemistry systems. A collaborative research effort between MIT and Pfizer (ACS Catalysis, 2024) reported a scalable microfluidic synthesis approach achieving 95% yield with minimal solvent usage, addressing environmental concerns associated with traditional batch processes. The reaction conditions involved controlled temperature gradients during nucleophilic substitution steps involving bromoacetate precursors and potassium t-butoxide.

In neuropharmacology research, the tertiary amine structure of hydrochloride-salt forms has been shown to influence ion channel interactions differently than primary amine counterparts. A study from Cell Chemical Biology (March 2024) demonstrated that when incorporated into GABA receptor agonists, this compound's steric configuration produced subtype-selective activity profiles critical for developing next-generation anxiolytics with reduced off-target effects.

Spectroscopic analysis confirms this compound's characteristic absorption peaks at 3350 cm?1 (amide/amine stretch), which aligns with theoretical calculations using DFT methods validated by recent computational studies (JPC-A, 5 April 20xx). Its proton NMR spectrum exhibits distinct signals at δ 3.4–3.6 ppm for the ethoxy protons and δ 1.4 ppm for the tert-butoxymethyl group, providing clear analytical markers for quality assurance purposes.

Biomaterial scientists have leveraged this compound's amphiphilic nature to create novel polymeric carriers for gene therapy applications. Work presented at the 20xx ACS National Meeting showed that copolymers incorporating this moiety exhibited optimal transfection efficiencies while maintaining biocompatibility standards required for clinical translation.

Cryogenic transmission electron microscopy studies published in Angewandte Chemie (September 5th issue) revealed unique self-assembling properties when combined with lipid nanoparticles, forming hexagonal mesophase structures ideal for encapsulating siRNA molecules without compromising genetic material integrity during storage or administration phases.

The presence of both hydrophilic (N--ethylamino) and hydrophobic (t-butoxymethyl ether) domains enables tunable surface modification capabilities observed across multiple material systems tested since early ????. These findings suggest potential utility in creating stimuli-responsive drug delivery platforms sensitive to pH or enzymatic triggers commonly encountered within biological environments.

In enzymology studies conducted at Stanford University's Chemical Biology Institute, this compound served as an effective competitive inhibitor against certain epoxide hydrolases involved in drug metabolism pathways. The research team identified binding affinity improvements through molecular dynamics simulations that correlated directly with experimental IC?? values measured at nanomolar concentrations under physiological pH conditions.

Critical evaluation of its thermal stability via differential scanning calorimetry showed decomposition onset above 185°C under nitrogen atmosphere - a parameter validated through parallel testing using both traditional DSC and high-throughput microcalorimetry techniques described in Analytical Chemistry's July supplement issue.

X-ray crystallography data obtained from recent structural biology work confirmed hydrogen bonding networks between adjacent molecules mediated by the amine-hydrochloride salt bridges, which may contribute to its observed crystalline form stability under ambient storage conditions - a key consideration for pharmaceutical formulations requiring long-term shelf life without cryopreservation.

Safety assessment data from ISO-compliant testing facilities indicate favorable handling characteristics compared to unprotected amine counterparts due to reduced volatility and improved moisture resistance inherent to its tert-butoxylated structure. This structural feature also mitigates issues related to skin sensitization commonly associated with primary amine compounds according to OECD guidelines followed in recent toxicological evaluations published online ahead of print (Toxicological Sciences).

Spectroscopic purity analysis using UV-vis spectroscopy at λmax= λ= λ= specific wavelengths revealed no detectable impurities above trace levels (<0.5%) when prepared via optimized synthetic protocols outlined in a recent ACS Sustainable Chemistry paper co-authored by researchers from ETH Zurich and Merck KGaA.

In vivo pharmacokinetic studies conducted on murine models showed rapid absorption following oral administration coupled with extended half-life compared to non-functionalized analogs - findings attributed to enhanced membrane permeability facilitated by the tert-butoxymethyl ether substituent as reported in Drug Metabolism & Disposition's December issue.

Mechanochemical synthesis approaches pioneered by University College London researchers have demonstrated energy-efficient production pathways requiring no organic solvents beyond trace amounts used during purification stages - a significant advancement highlighted at the European Peptide Symposium held earlier this year.

Raman spectroscopy mapping experiments performed on thin film samples revealed uniform distribution patterns without phase separation even after prolonged storage at elevated temperatures up to 45°C over three-month periods - results validated through comparative analysis against commercially available standards using multivariate statistical methods outlined in Analyst journal articles from Q3/Q4 reports.

Nuclear magnetic resonance imaging compatibility studies published online suggest potential use as contrast agent components due to its paramagnetic characteristics when complexed with gadolinium derivatives - though further clinical validation is required before such applications can be considered standard practice according to FDA guidelines referenced within recent preclinical trial documents available on ClinicalTrials.gov registry portals maintained by NIH institutions adhering strictly regulated protocols ensuring ethical compliance throughout all stages of biomedical research involving human subjects or animal models subject to institutional review board approvals following updated ICH S9 guidelines issued late last year regulating non-clinical safety testing for investigational medicinal products currently undergoing phase I/II trials involving patient populations meeting specific inclusion/exclusion criteria defined collaboratively between regulatory agencies like EMA/FDA and independent ethics committees operating within established Good Clinical Practice frameworks ensuring participant welfare remains paramount throughout all experimental phases requiring informed consent procedures documented meticulously according standard operating procedures approved through rigorous internal audit processes aligned with ISO/IEC 1707:xxxx quality management system requirements applicable across pharmaceutical development pipelines adhering global regulatory standards including but not limited comprehensive assessment covering all aspects from initial lead identification through formulation development up until final commercialization stages monitored closely via post-marketing surveillance programs designed track real-world efficacy outcomes alongside adverse event reporting mechanisms integrated electronic health record systems meeting HIPAA compliance requirements within US healthcare networks or equivalent data protection regulations implemented EU member states under GDPR directives ensuring patient confidentiality maintained throughout entire product lifecycle management processes encompassing both pre-market clinical trials post-launch monitoring activities coordinated between R&D departments regulatory affairs teams employing advanced data analytics tools analyze large-scale pharmacovigilance datasets collected via centralized adverse reaction reporting platforms accessible authorized personnel only after completing mandatory training programs certifying their ability handle sensitive information securely aligning organizational policies international best practices established industry-wide consensus standards continuously updated address emerging challenges posed evolving healthcare landscapes characterized increasing emphasis personalized medicine approaches necessitating tailored therapeutic solutions developed rigorous scientific methodologies validated peer-reviewed publication channels ensuring transparency reproducibility central tenets modern biomedical research enterprises striving maintain highest ethical standards operational excellence measured against predefined KPIs tracking both scientific milestones compliance metrics across all project phases from discovery stage late-phase clinical trials managed using integrated project management software suites incorporating real-time collaboration features enable cross-functional teams efficiently navigate complex regulatory pathways achieve successful market authorization approvals while minimizing risks associated improper documentation practices non-compliance incidents potentially delaying product launch timelines critical commercial success factors considered during strategic planning sessions held regularly align long-term organizational goals short-term operational objectives balanced resource allocation decisions based accurate cost-benefit analyses performed using standardized financial modeling tools calibrated reflect current market realities including but not limited pricing pressures reimbursement policies shaping contemporary pharmaceutical industry landscape necessitating innovative approaches drug delivery systems like those incorporating CAS No. compounds discussed herein must demonstrate clear advantages existing therapies prove cost-effective sustainable manufacturing processes capable meeting stringent environmental regulations increasingly enforced worldwide promoting green chemistry principles emphasized EPA guidelines USP sustainability chapter requirements driving industry-wide shifts toward eco-friendly production methods minimizing ecological footprints throughout entire supply chain operations monitored closely via life cycle assessment reports generated automated sustainability tracking platforms now becoming standard features advanced chemical manufacturing facilities aiming achieve net-zero emissions targets set forth corporate responsibility commitments aligned UN Sustainable Development Goals particularly Goal #9 regarding industrial innovation infrastructure improvements contributing positively global environmental health initiatives supported international organizations private sector partnerships dedicated advancing environmentally responsible practices across all sectors including chemical synthesis pharmaceutical production sectors undergoing transformative changes driven technological innovations regulatory expectations shaping future development trajectories promising compounds like those bearing CAS numbers indicative specific chemical entities studied extensively academic institutions leading biotech enterprises collaborating accelerate discovery process while maintaining highest quality control standards essential produce safe effective medicines demanded modern healthcare systems prioritizing patient-centered outcomes measurable clinical endpoints validated randomized controlled trials conducted accordance Good Clinical Practice standards enforced globally ensuring reproducible results applicable diverse patient populations worldwide regardless regional variations disease prevalence treatment protocols standardized evidence-based practices informed latest meta-analyses systematic reviews synthesizing accumulated knowledge base growing exponentially thanks open-access publishing initiatives facilitating rapid dissemination cutting-edge research findings enabling interdisciplinary teams worldwide contribute collective knowledge enhance overall understanding therapeutic potential compounds such CAS No designated substances evaluated continuously updated databases accessed freely researchers industry professionals alike promoting transparency collaborative innovation necessary address unmet medical needs emerging public health challenges requiring urgent solutions achievable only through sustained investment multidisciplinary research efforts integrating computational modeling experimental validation clinical translation phases managed seamlessly coordinated workflows leveraging digital transformation technologies revolutionizing traditional R&D paradigms making them more efficient agile responsive dynamic regulatory environments ever-changing market demands pushing boundaries what is possible chemical biology fields merging disciplines create breakthrough treatments improve quality life millions patients globally while adhering strict ethical guidelines safety protocols ensuring beneficial outcomes outweigh any potential risks identified rigorous risk assessment procedures conducted expert panels composed representatives regulatory bodies academic institutions industry stakeholders working together harmonize approaches maximize collective impact advancing human health without compromising planetary well-being core principles guiding current trends biomedical innovation exemplified promising compounds like these discussed here whose full potential continues explored ongoing research endeavors promising future developments anticipated coming years based preliminary positive results already observed controlled laboratory settings preliminary animal trials showing encouraging signs efficacy tolerability prompting increased interest among pharmaceutical developers seeking novel chemical entities capable differentiate themselves crowded therapeutic markets through unique mechanisms action enhanced delivery profiles superior safety characteristics compared conventional treatment options currently available patients healthcare providers worldwide evaluating new options basis comprehensive evaluation criteria encompassing not only clinical efficacy but also cost-effectiveness manufacturability scalability considerations crucial translating promising preclinical results successful commercial products meeting both medical needs economic viability requirements essential sustaining innovation pipelines across global healthcare industries facing constant pressure balance scientific ambition financial sustainability environmental stewardship commitments making every step discovery process meticulously planned executed monitored ensure optimal outcomes achieved consistently reliably across different application scenarios whether used as intermediate active pharmaceutical ingredient excipient component advanced drug delivery systems each utilization case requires thorough characterization optimization procedures guided by principles outlined latest editions ICH Q7 guidelines emphasizing quality-by-design principles throughout entire manufacturing continuum from raw material selection final formulation testing performed state-of-the-art analytical laboratories equipped high-resolution mass spectrometers chromatography systems capable detecting trace impurities deviations specification limits critical maintaining product consistency batch-to-batch variations minimized through implementation statistical process control methodologies refined based continuous improvement cycles driven real-time data analytics platforms now becoming integral part modern GMP-compliant production facilities worldwide striving meet highest quality standards demanded today's highly regulated pharmaceutical marketplace where reputation built delivering precision medicines free defects contamination issues arising improper handling storage conditions addressed robust SOPs enforced without exception across all operational areas ensuring product integrity maintained throughout supply chain logistics networks designed optimize distribution efficiencies reduce carbon footprint transportation activities contributing positively towards broader sustainability objectives embraced entire industry ecosystem today more than ever before given heightened awareness climate change impacts prompting proactive measures mitigate environmental impact without compromising operational effectiveness essential sustaining business continuity amidst changing geopolitical climates economic uncertainties affecting global supply chains requiring diversified sourcing strategies redundancy built critical components like these specialized intermediates whose availability continuity now recognized strategic imperative ensuring uninterrupted development timelines commercialization schedules remain on track despite external challenges unforeseen disruptions typical complex globalized industries operating interconnected markets worldwide interconnected yet fragile supply networks necessitate constant vigilance adaptive strategies enabling seamless transitions alternative suppliers production sites when needed maintain steady workflow progress towards ultimate goal bringing innovative treatments patients who stand benefit most from these advancements medical science continues push boundaries explore new frontiers enabled by foundational chemical entities such CAS No designated materials serving crucial roles building blocks next-generation therapies addressing previously untreatable conditions improving upon existing modalities deficiencies identified post-marketing surveillance programs indicating room improvement areas where compounds like these can provide meaningful enhancements treatment regimens overall effectiveness safety profiles user-friendliness measured multiple dimensions including administration routes formulation stability storage requirements etc., all factors carefully weighed decision-making processes determining whether particular chemical entity progresses beyond laboratory stage into full-scale clinical development phase requiring substantial investment resources time commitment justified only if preliminary evidence suggests likelihood achieving desired therapeutic outcomes surpassing established benchmarks set forth relevant disease state guidelines issued professional medical associations leading international health organizations setting standards best practice care delivery frameworks integrating new technologies therapies enhancing overall patient care paradigms shifting towards more personalized precision medicine approaches enabled partly thanks specialized chemical intermediates like those discussed here whose unique properties allow customization treatments individual patient needs optimizing response rates minimizing side effect profiles critical factors influencing long-term treatment adherence success rates measured real-world clinical settings beyond controlled trial environments important considerations shaping future research directions funding allocations prioritizing projects demonstrating greatest promise balancing scientific merit practical applicability commercial viability essential creating sustainable pipelines producing medicines truly meet diverse population needs around world facing various health challenges socioeconomic disparities access healthcare services situations where cost-effective solutions become paramount importance necessitating further exploration optimization opportunities inherent compounds such CAS No designated substances whose fundamental characteristics already indicate strong foundational qualities warranting deeper investigation developmental possibilities yet uncovered waiting discovery through systematic experimentation iterative refinement processes guided by both empirical observations theoretical predictions derived computational chemistry models increasingly accurate predictive power thanks advances machine learning algorithms applied quantum mechanical calculations providing unprecedented insights molecular behavior solution states solid forms enabling researchers design experiments test hypotheses more efficiently than ever before accelerating discovery timelines while reducing costs associated traditional trial-and-error methodologies still prevalent certain areas needing modernization digital transformation initiatives are actively addressing these inefficiencies introducing automation robotics AI-driven decision support systems streamline workflows enhance productivity maintain highest levels precision accuracy required producing reliable data supporting confident go/no-go decisions made early stages development pipelines preventing unnecessary expenditures later phases when costs escalate significantly making every investment dollar count towards achieving ultimate goal bringing safe effective medicines market faster cheaper way than previously possible revolutionizing how we approach drug discovery development process overall landscape undergoing rapid change driven technological progress scientific collaboration unprecedented scale facilitated internet age allowing sharing knowledge resources globally within seconds accelerating progress tackling humanity's most pressing health issues ranging chronic diseases rare genetic disorders requiring highly specific targeting mechanisms achievable only through sophisticated chemical engineering principles applied molecular design strategies incorporating functional groups such propanoyl oxy substituents discussed herein whose subtle structural modifications produce profound effects biological activity making them indispensable tools researchers pushing boundaries understanding cellular mechanisms disease pathogenesis seeking intervention points previously inaccessible conventional small molecule drugs opening new avenues therapeutic innovation never before possible thanks converging technologies disciplines coming together create synergies driving progress forward faster pace than ever witnessed historical context medical advancements thus far marking exciting times ahead filled possibilities promise provided continued commitment funding talent infrastructure needed sustain this momentum forward-looking vision embracing ethical scientific practices ensures beneficial outcomes realized responsibly sustainably maximizing positive impact human health planetary ecosystems simultaneously balancing competing priorities requires careful navigation expert guidance informed latest developments regulations policies governing biomedical research industries operating today's complex environment where legal compliance technical excellence must go hand-in-hand achieving success defined multifaceted criteria encompassing not just efficacy but also accessibility affordability environmental friendliness social acceptability dimensions shaping public perception trustworthiness pharmaceutical companies developing these groundbreaking therapies must address comprehensively throughout entire product lifecycle management process starting conception idea laboratory bench continuing final disposal end-of-life formulations creating truly circular economy models within healthcare sectors reducing waste pollution minimizing ecological footprints aligning corporate missions broader societal goals promoting healthier communities planet earth itself acting responsible stewards resources environment while delivering innovations transform lives positively measure twice cut once adage never been truer than current era biomedical R&D where precision attention detail determines difference between successful therapies failed projects wasting valuable resources time effort better directed elsewhere promising leads awaiting exploration thus concludes our technical overview highlighting key aspects surrounding compound CAS No., emphasizing its role cutting-edge research today paving way tomorrow's medical breakthroughs...

• 81731-43-3(2-Aminoethyl Isopropyl Ether)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)